IL4

Across TCGA pan-cancer cohorts, IL4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated IL4 data layer compared with 21 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher IL4 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated IL4 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where IL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	II,III,IV	0.839	0.617	.009	10	view →
LUAD	DFS	Tertile	III,IV	0.651	1.000	.040	8	view →
CCRCC	DFS	Tertile	II,III,IV	0.434	0.792	.029	4	view →
GBM	DFS	Median	All	0.245	0.514	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

IL4–HNSC (OS)

Open the HNSC breakdown →